Hims & Hers introduced a $49 per month compounded semaglutide pill in early February— then pulled it from the market two days ...

‘It’s not an easy pill to take’: The first highly anticipated GLP-1 pill is here, but physicians aren’t sure it has the ...

When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and ...

The Grand Rapids-based chain announced Tuesday it is making Wegovy and Ozempic more affordable to customers by accepting ...

Feb 10 (Reuters) - Novo Nordisk's U.S. patent lawsuit against Hims & Hers, filed on Monday, ‌marks ​a new front in the Danish ...

Eli Lilly ( LLY 1.41%) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit ...

The U.S. Food and Drug Administration said a television advertisement for Novo Nordisk's weight-loss pill is "false or ...

On Feb. 6, 2026, FDA announced that it would take action to restrict access to GLP-1 ingredients for non-FDA approved compounded drugs. On the same day, the HHS General Counsel announced on social ...

Healthcare experts answer the most common questions about TrumpRx, plus who this new government portal is best for.

The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing ...

Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.